/BEAT
BEAT Stock - HeartBeam, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$3.10+14.39%
+$0.39 (+14.39%) • Dec 19
88
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+41.3%upside
Target: $4.38
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BEAT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.07 – $3.13
TARGET (TP)$4.38
STOP LOSS$2.85
RISK/REWARD1:5.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.58
52W High$4.00
52W Low$0.54
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-19,887,000 | $-15,314,000 | $-13,031,000 | $-2,285,000 | $-788,000 |
| Net Income | $-19,448,000 | $-14,639,000 | $-12,962,000 | $-4,428,000 | $-1,068,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.73 | $-0.72 | $-1.59 | $-0.56 | $-0.14 |
Company Overview
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 55.9% Upside
Now
$3
Low
$5
Average
$8
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | The Benchmark Company | Upgrade | Buy | $8 |
| December 8th 2025 | H.C. Wainwright | Initiation | Buy | $2.5 |
| October 31st 2025 | Roth Capital | Initiation | Buy | $4 |
Earnings History & Surprises
BEATBeat Rate
19%
Last 16 quarters
Avg Surprise
-50.5%
EPS vs Estimate
Beats / Misses
3/13
Last 12 quarters
Latest EPS
$-0.15
Q4 2025
EPS Surprise History
Q1 24
-8.3%
$-0.13vs$-0.12
Q2 24
-13.3%
$-0.17vs$-0.15
Q3 24
-18.8%
$-0.19vs$-0.16
Q4 24
-11.8%
$-0.19vs$-0.17
Q1 25
+5.3%
$-0.18vs$-0.19
Q2 25
-20.0%
$-0.18vs$-0.15
Q3 25
+6.3%
$-0.15vs$-0.16
Q4 25
+6.3%
$-0.15vs$-0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.15 | $-0.18 | -20.0% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.16 | $-0.19 | -18.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.15 | $-0.17 | -13.3% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.10 | $-0.16 | -60.0% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.33 | $-0.50 | -51.5% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $0.37 | $-0.45 | -221.6% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.30 | $-0.44 | -46.7% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.27 | $-0.43 | -59.3% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.19 | $-0.27 | -42.1% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.11 | $-0.40 | -263.6% | ✗ MISS |
Q4 2021 | Dec 16, 2021 | — | $-0.15 | — | — |
Q4 2021 | Nov 18, 2021 | — | $-0.12 | — | — |
Latest News
Benchmark Upgrades HeartBeam to Buy, Maintains Price Target to $8
📈 PositiveBenzinga•Dec 11, 2025, 01:32 PM
HC Wainwright & Co. Maintains Buy on HeartBeam, Raises Price Target to $5.5
📈 PositiveBenzinga•Dec 10, 2025, 06:12 PM
Heartbeam shares are trading higher after the company announced it received FDA clearance for its 12-lead electrocardiogram synthesis software for the assessment of arrhythmias.
📈 PositiveBenzinga•Dec 10, 2025, 01:57 PM
HeartBeam Says It Won FDA 510(k) Clearance For First-Ever Cable-Free Synthesized 12-Lead ECG Software For At-Home Arrhythmia Assessment After Successful Appeal
📈 PositiveBenzinga•Dec 10, 2025, 12:03 PM
HC Wainwright & Co. Initiates Coverage On HeartBeam with Buy Rating, Announces Price Target of $2.5
📈 PositiveBenzinga•Dec 8, 2025, 12:25 PM
Heartbeam shares are trading higher after the company recently announced its regulatory strategy following the FDA's Not Substantially Equivalent decision on its 12-lead Electrocardiogram Synthesis Software.
📈 PositiveBenzinga•Nov 28, 2025, 04:23 PM
HeartBeam To Pursue Parallel Appeal And 510(k) Resubmission Paths Following NSE Decision
➖ NeutralBenzinga•Nov 26, 2025, 09:42 PM
HeartBeam Announces Regulatory Strategy Following Receipt Of Not Substantially Equivalent Decision On Its 510(K) Submission For 12-Lead Electrocardiogram Synthesis Software
📉 NegativeBenzinga•Nov 26, 2025, 09:38 PM
Heartbeam shares are trading lower after the company announced that the FDA issued a "Not Substantially Equivalent" letter regarding its 510(k) submission for its 12-Lead ECG Synthesis Software.
📉 NegativeBenzinga•Nov 21, 2025, 06:58 PM
Heartbeam Receives NSE Letter From FDA For 12-Lead ECG Synthesis Software; Evaluating Launch Of FDA-Cleared 3d ECG System; To Work With FDA To Resolve NSE Issue
➖ NeutralBenzinga•Nov 21, 2025, 02:55 PM
HeartBeam Q3 EPS $(0.15) Misses $(0.12) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:02 PM
HeartBeam Partners With HeartNexus To Provide 24/7 Cardiology Reader Service To Support Patients Experiencing Cardiac Symptoms Outside Of Traditional Healthcare System
📈 PositiveBenzinga•Oct 28, 2025, 11:14 AM
HeartBeam Announces Study Demonstrating There Were No Significant Differences In The Detection Of Atrial Fibrillation, Atrial Flutter And Sinus Rhythm When Co.'s Deep Learning Algorithms Were Applied To The HeartBeam System Or To Standard 12-Lead ECGs.
➖ NeutralBenzinga•Sep 8, 2025, 11:10 AM•Also:
HeartBeam Cuts Costs Awaits FDA Decision
➖ NeutralThe Motley Fool•Aug 13, 2025, 09:23 PM
Frequently Asked Questions about BEAT
What is BEAT's current stock price?
HeartBeam, Inc. (BEAT) is currently trading at $3.10 per share. The stock has moved +14.39% today.
What is the analyst price target for BEAT?
The average analyst price target for BEAT is $4.38, based on 1 analyst.
What sector is HeartBeam, Inc. in?
HeartBeam, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is BEAT's market cap?
HeartBeam, Inc. has a market capitalization of $0.11 billion, making it a small-cap company.
Does BEAT pay dividends?
No, HeartBeam, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
HOWL
Werewolf Therapeutics, Inc.
$0.69
Mkt Cap: $0.0B
INKT
MiNK Therapeutics, Inc.
$11.59
Mkt Cap: $0.1B
IOBT
IO Biotech, Inc.
$0.66
Mkt Cap: $0.0B
MDAI
Spectral AI, Inc.
$1.55
Mkt Cap: $0.0B
ONMD
OneMedNet Corporation
$1.31
Mkt Cap: $0.0B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
Explore stocks similar to BEAT for comparison